http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2761048-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1d939c0d98d930384292e9581806d33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00 |
| filingDate | 2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_444bd4ad4bc318d5f9514e9b8d347c14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d5e64e698062a0fbf66c665aefbd1c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59432e27f07f901fb15567ff1017d61a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87172b7cb1596b65732fd9657d634d22 |
| publicationDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2761048-C1 |
| titleOfInvention | Method for selecting a method for treating patients with primary open-angle glaucoma |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to ophthalmology. The stage of glaucoma, the level of intraocular pressure (IOP level), the progression of POAG according to static perimetry data, the presence of local antihypertensive therapy or selective laser trabeculoplasty (SLT), the tolerance of antihypertensive drugs, the presence of risk factors are assessed, while the suspicion of glaucoma is estimated at 1 point, the initial stage - 2 points, advanced - 4 points, chronic - 6 points. Normal IOP level - 0 points; borderline value of IOP - 1 point; moderately increased - 3 points; high - 5 points. Progression: not detected - 0 points; insufficient data in the absence of 3 studies - 3 points; decrease during the year in VFI less than 1% and MD by less than 0.3 dB - 2 points; decrease in VFI from 1 to 3% and MD by 0.3-1 dB - 4 points; VFI over 3% and MD over 1 dB - 8 points. Local antihypertensive therapy was not previously performed - 0 points, initial therapy - monotherapy with prostaglandin analogs, β-blockers, or α-adrenomimetics, or carbonic anhydrase inhibitors, or SLT - 1 point. Enhanced - monotherapy with prostamides or non-fixed combinations of two monopreparations - 3 points; combined - fixed combinations of an analogue of prostaglandin or prostamide with timolol or a combination of three active topical antihypertensive substances, with the exception of prostamides, in different combinations - 4 points. Maximum - a combination of three active antihypertensive substances, including prostamide, or local antihypertensive therapy, supplemented with systemic drugs - 8 points, tolerance of antihypertensive drugs is good - 0 points, poor - 2 points, absence or one of the risk factors - 0 points, two or more - 2 points. With a score of 0-6, follow-up without treatment, 7-10 - prescribing starting therapy or SLT, 11-13 - intensified therapy, 14-16 - combined antihypertensive therapy, informing the patient about the possibility of surgical treatment, 17-19 - maximum antihypertensive therapy, informing the patient about the possibility of surgical treatment, more than 19 - the appointment of antiglaucoma surgery.EFFECT: method allows choosing the most optimal and individual tactics for treating a patient with open-angle glaucoma at various stages of the disease.1 cl, 4 tbl, 4 ex |
| priorityDate | 2021-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.